Navigation Links
Lilly Discontinues One of Three Phase 3 Rheumatoid Arthritis Registration Studies for Tabalumab
Date:12/13/2012

INDIANAPOLIS, Dec. 13, 2012 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced today that it will stop one of three Phase 3 rheumatoid arthritis (RA) registration studies of tabalumab, an anti-BAFF monoclonal antibody, due to insufficient efficacy. The decision followed a planned interim futility analysis of the FLEX-M study investigating tabalumab, also known as LY2127399, for the treatment of patients with moderate-to-severe RA who had an inadequate response to methotrexate therapy. The decision was not based on safety concerns, and patients currently enrolled in other tabalumab RA studies will continue treatment.

The FLEX-M study was designed to support registration of tabalumab as a potential treatment for RA, including an assessment of its effect on structural progression. Lilly continues to evaluate tabalumab in two other Phase 3 RA registration studies as well as an open-label extension study and several other smaller studies. Lilly is suspending enrollment of new patients in the RA program until additional analysis from other ongoing RA studies is completed in early 2013. These other studies are in different patient populations.

Phase 3 studies for systemic lupus erythematosus are ongoing and will continue to enroll new patients. Currently, there is no evidence to suggest that efficacy results from the FLEX-M study in RA are indicative of potential efficacy in the lupus population. Lilly remains committed to the ongoing Phase 3 lupus program.

"The results of this study were unexpected given the data generated in earlier Phase II clinical studies of tabalumab," said Eiry Roberts, M.D., vice president of autoimmune product development at Lilly. "We remain committed to patients with rheumatoid arthritis and lupus and will move rapidly to evaluate the impact of these data on the overall tabalumab clinical development program. Beyond tabalumab,
'/>"/>

SOURCE Eli Lilly and Company
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Lilly Provides Update on Next Steps for Solanezumab
2. Lilly to Expand Indianapolis Insulin Manufacturing Operations
3. Lilly Names Melissa Barnes Chief Ethics and Compliance Officer and Senior Vice President; Announces Retirement of Anne Nobles
4. Lilly Celebrates 18th Consecutive Year as One of Working Mothers 100 Best Companies
5. Boehringer Ingelheim and Lilly introduce the My Well Planner Lifestyle Improvement Program for Adults with Type 2 Diabetes
6. Lilly Announces Results From Lung Cancer Study
7. Lilly Announces Retirement of Robert Armitage, Names Michael Harrington Senior Vice President and General Counsel
8. Lilly Stops Phase III Development of Pomaglumetad Methionil For the Treatment of Schizophrenia Based on Efficacy Results
9. U.S. Court of Appeals Upholds Validity of Lillys Alimta Compound Patent
10. Lilly Revises 2012 Reported Guidance to Reflect Income from Early Payment of Amylin Obligations
11. Lilly Announces Study Results Regarding Postmenopausal Women with Back Pain Caused by Vertebral Fractures
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... 2014 Reportlinker.com announces that a new ... catalogue: Insulin Pump ... http://www.reportlinker.com/p01957812/Insulin-Pump-Market--Forecast-–-Worldwide-Analysis.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Medical_Equipment_and_Supply ... Insulin Pumps are gaining strong acceptance ...
(Date:1/15/2014)... , Jan. 15, 2014  Zafgen, Inc., a leading ... of severely obese patients, today announced initial results ... selective inhibitor of methionine aminopeptidase 2 (MetAP2), in ... of genetic obesity.  These results showed improvements in ...
(Date:1/14/2014)... Brandeis Medical Center, led by Dr. Emmanuel Brandeis , offers ... tattoo removal experience with the advanced Astanza Duality laser and a ... cosmetic services with cutting edge medical technology and offering expert medical ... has seen a dramatic increase in the presence of tattoo ...
Breaking Medicine Technology:Insulin Pump Market & Forecast - Worldwide Analysis 2Insulin Pump Market & Forecast - Worldwide Analysis 3Insulin Pump Market & Forecast - Worldwide Analysis 4Insulin Pump Market & Forecast - Worldwide Analysis 5Insulin Pump Market & Forecast - Worldwide Analysis 6Insulin Pump Market & Forecast - Worldwide Analysis 7Insulin Pump Market & Forecast - Worldwide Analysis 8Insulin Pump Market & Forecast - Worldwide Analysis 9Insulin Pump Market & Forecast - Worldwide Analysis 10Insulin Pump Market & Forecast - Worldwide Analysis 11Insulin Pump Market & Forecast - Worldwide Analysis 12Insulin Pump Market & Forecast - Worldwide Analysis 13Insulin Pump Market & Forecast - Worldwide Analysis 14Insulin Pump Market & Forecast - Worldwide Analysis 15Insulin Pump Market & Forecast - Worldwide Analysis 16Insulin Pump Market & Forecast - Worldwide Analysis 17Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 2Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 3Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 4Beverly Hills Physician Features Tattoo Removal with the Astanza Duality Laser, Offers $99 Special 2
... , , , , , BEIJING ... SVA),a leading China -based vaccine manufacturer, today announced that it ... of the,company in an underwritten public offering. Sinovac plans to grant ... shares,to cover overallotments. , Sinovac plans to ...
... , SAN DIEGO , Jan. 20, 2010 Amylin ... Call for the fourth quarter and full year 2009 on Wednesday, ... PT . Daniel M. Bradbury , Amylin,s president and chief executive ... release financial results for the fourth quarter and year ended December ...
Cached Medicine Technology:Sinovac Announces Plan to Launch Offering of Common Shares 2Sinovac Announces Plan to Launch Offering of Common Shares 3Amylin Pharmaceuticals to Webcast Year-End Financial Results 2
(Date:4/17/2014)... University School of Medicine (BUSM) have discovered that ... an experimental model. The findings, reported in the ... , may lead to more effective treatments for ... of the leading causes of illness and death ... impact by limiting the productivity of workers and ...
(Date:4/17/2014)... off depression among retirees, particularly among those who live ... The Journals of Gerontology, Series B: Psychological Sciences and ... Use and Depression Among Retired Older Adults in the ... that Internet use reduced the probability of a depressed ... , Late-life depression affects between 5 and 10 million ...
(Date:4/17/2014)... days to find a colored ribbon representing a disease. A ... what color ribbon does one think of with lung cancer?, ... many suffering from the disease, black may be the only ... of lung cancer patients, primarily smokers between the ages of ... the stigma often felt by these patients, the emotional toll ...
(Date:4/17/2014)... is less than 40 years away from a food ... governments, according to a top scientist at the U.S. ... human history, food production will be limited on a ... energy," said Dr. Fred Davies, senior science advisor for ... become as politically destabilizing by 2050 as energy issues ...
(Date:4/17/2014)... they suffer a cardiac arrest outside of a hospital ... to new research conducted at St. Michael,s Hospital. , ... arrest get adrenaline, which has been the drug recommended ... Lin, an emergency physician and trauma team leader at ... survival rates of patients who suffer a cardiac outside ...
Breaking Medicine News(10 mins):Health News:BUSM researchers find anti-seizure drug may reduce alcohol consumption 2Health News:Internet use may cut retirees' depression 2Health News:Unraveling the 'black ribbon' around lung cancer 2Health News:Food shortages could be most critical world issue by mid-century 2Health News:Adrenaline does little to increase patient's survival after cardiac arrest 2
... 1 (HealthDay News) -- Black and Hispanic children with frequent ... care than white children, say U.S. researchers. They analyzed ... and found that each year about 4.6 million children have ... 12 months. Overall, 3.7 percent of children with frequent ...
... Alexandria, VA Racial and ethnic disparities among children with ... according to new research published in the November 2010 issue ... Ear infections are one of the most common health ... by their third birthday. Annual costs in the United States ...
... lacked a reliable screening test for it. Now researchers at ... report the PHQ-9 (Patient Health Questionnaire - 9 item) is ... Led by Laura P. Richardson, MD, MPH, the team ... 442 teenage patients, age 13-17, at Group Health. The test ...
... have developed an efficient method for extracting and archiving ... keep track of estimated radiation dose delivered to each ... informed health care decisions and improve patient safety, according ... Journal of the American College of Radiology ( www.jacr.org ...
... to designing effective drug treatments that are precisely tailored to ... any of which can trigger the body,s immune system defenses. ... the latest issue of Nature Medicine online Oct. ... three weeks can pinpoint the unique binding site or ...
... Hepatitis C patients who receive a liver from a white ... receive a liver from a black donor, researchers have found. ... a liver from a white donor, the study authors noted. ... 165 hepatitis C patients who received a liver transplant at ...
Cached Medicine News:Health News:Race, Income Affect Care for Ear Infections: Study 2Health News:Racial and ethnic disparities impact care for children with frequent ear infections 2Health News:Racial and ethnic disparities impact care for children with frequent ear infections 3Health News:Researchers develop successful method for extracting and archiving patient radiation dose info 2Health News:Immune system's bare essentials used to speedily detect drug targets 2Health News:Immune system's bare essentials used to speedily detect drug targets 3
Our smallest port is available with or without a COOK Peel-Away Introducer Set....
The mid-sized polysulfone is about 3/4 the diameter and half the weight of the standard model. The silicone catheter has an I.D. of 0.9 mm....
The WaveMap provides immediate clinical decision making information with automatic calculation of pressure gradients and FFR measurements.,SmartWire Pressure Guide Wire - The intelligent choice in ...
Used for vascular access. Supplied sterile in peel-open packages. Intended for one-time use....
Medicine Products: